BIM
CYTK icon

Bogle Investment Management’s Cytokinetics CYTK Stock Holding History

Bogle Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-409,679
Closed -$4.96M – 300
2017
Q2 		$4.96M Buy
409,679
+200,898
+96% +$2.79M 0.36% 107
2017
Q1 		$2.68M Buy
+208,781
New +$2.44M 0.19% 134
2016
Q1 		– Sell
-377,801
Closed -$3.95M – 396
2015
Q4 		$3.95M Buy
377,801
+161,433
+75% +$1.58M 0.28% 115
2015
Q3 		$1.45M Buy
216,368
+100,989
+88% +$689K 0.1% 229
2015
Q2 		$775K Buy
115,379
+83,430
+261% +$547K 0.06% 284
2015
Q1 		$216K Buy
+31,949
New +$239K 0.01% 330
2014
Q4 		– Sell
-319,647
Closed -$1.13M – 366
2014
Q3 		$1.13M Sell
319,647
-233,361
-42% -$980K 0.07% 237
2014
Q2 		$2.64M Buy
553,008
+198,828
+56% +$1.21M 0.18% 153
2014
Q1 		$3.36M Buy
+354,180
New +$3.2M 0.23% 143
2013
Q4 		– Sell
-447,035
Closed -$3.38M – 311
2013
Q3 		$3.38M Buy
+447,035
New +$4.79M 0.34% 111

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Bogle Investment Management's CYTK Position: Q3 2017 in Review

Bogle Investment Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 409,679 shares — an estimated $4.96M sold.

Bogle Investment Management first reported a position in CYTK in Q3 2013 and held it in 10 quarters. The position peaked at $4.96M in Q2 2017. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

  • Bogle Investment Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
  • Bogle Investment Management sold 409,679 Cytokinetics shares in Q3 2017, an estimated $4.96M.
  • Bogle Investment Management first reported a position in Cytokinetics in Q3 2013 and held it in 10 quarters.
  • Bogle Investment Management's Cytokinetics position peaked at $4.96M in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Bogle Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.